In vivo evaluation of a lead-labeled monoclonal antibody using the DOTA ligand
暂无分享,去创建一个
M. Brechbiel | J. Schlom | J. Carrasquillo | M. Roselli | D. Milenic | O. Gansow | C. Pippin | D. Colcher | R. Lambrecht | Thomas J. McMurray | Thomas J. McMurray
[1] G. Denardo,et al. Yttrium-90/indium-111-DOTA-peptide-chimeric L6: pharmacokinetics, dosimetry and initial results in patients with incurable breast cancer. , 1997, Anticancer research.
[2] I. Pastan,et al. Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[3] C. Sturiale,et al. Intralesional radioimmunotherapy of malignant gliomas. An effective treatment in recurrent tumors , 1994, Cancer.
[4] A. Maraveyas,et al. Pharmacokinetics and toxicity of an yttrium‐90‐citc‐dtpa‐hmfg1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer , 1994 .
[5] T. Koike,et al. Novel bifunctional macrocyclic chelating agents appended with a pendant-type carboxymethylamino ligand and nitrobenzyl group and stability of the 88YIII complexes , 1993 .
[6] T. Yokota,et al. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. , 1992, Cancer research.
[7] R. Delgado,et al. The stability of the metal complexes of cyclic tetra-aza tetra-acetic acids. , 1992, Talanta.
[8] M. Brechbiel,et al. Convenient synthesis of bifunctional tetraaza macrocycles. , 1992, Bioconjugate chemistry.
[9] T. Yokota,et al. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. , 1991, Cancer research.
[10] S. Larson. Choosing the right radionuclide and antibody for intraperitoneal radioimmunotherapy. , 1991, Journal of the National Cancer Institute.
[11] J. Schlom,et al. Monoclonal antibody-based therapy of a human tumor xenograft with a 177lutetium-labeled immunoconjugate. , 1991, Cancer research.
[12] R. Reilly. Radioimmunotherapy of malignancies. , 1991, Clinical pharmacy.
[13] K. D. Hardman,et al. In vivo tumor targeting of a recombinant single-chain antigen-binding protein. , 1990, Journal of the National Cancer Institute.
[14] S. Mirzadeh,et al. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. , 1990, Cancer research.
[15] J. Schlom,et al. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. , 1990, Journal of the National Cancer Institute.
[16] J. Schlom,et al. Staging of carcinoma of the breast using a hand-held gamma detecting probe and monoclonal antibody B72.3. , 1989, Surgery, gynecology & obstetrics.
[17] S. Mirzadeh,et al. Comparative biodistributions of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[18] K. D. Hardman,et al. Single-chain antigen-binding proteins. , 1988, Science.
[19] J. Schlom,et al. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. , 1988, Cancer research.
[20] D. E. Simpson,et al. Radioimmunoscintigraphy of colon cancer with iodine-131-labeled B72.3 monoclonal antibody. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[21] M. Brechbiel,et al. 212Bismuth linked to an antipancreatic carcinoma antibody: model for alpha-particle-emitter radioimmunotherapy. , 1988, Journal of the National Cancer Institute.
[22] D. Hnatowich,et al. Generator-produced yttrium-90 for radioimmunotherapy. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[23] M. Salvatore,et al. Immunoscintigraphy in the follow-up of patients operated on for carcinoma of the sigmoid and rectum , 1987, Diseases of the colon and rectum.
[24] D. E. Simpson,et al. New method for the chelation of indium-111 to monoclonal antibodies: biodistribution and imaging of athymic mice bearing human colon carcinoma xenografts. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[25] S. Larson,et al. Quantitative analyses of selective radiolabeled monoclonal antibody localization in metastatic lesions of colorectal cancer patients. , 1987, Cancer research.
[26] J L Humm,et al. Dosimetric aspects of radiolabeled antibodies for tumor therapy. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[27] S. Larson,et al. Prolonged binding of a radiolabeled monoclonal antibody (B72.3) used for the in situ radioimmunodetection of human colon carcinoma xenografts. , 1984, Cancer research.
[28] P. Hand,et al. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[29] P. Fraker,et al. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. , 1978, Biochemical and biophysical research communications.
[30] G. Denardo,et al. Overview of radioimmunotherapy in advanced breast cancer using I-131 chimeric L6. , 1994, Advances in experimental medicine and biology.
[31] A. Maraveyas,et al. Pharmacokinetics and toxicity of an yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer. , 1994, Cancer.
[32] P. Hand,et al. Therapeutic efficacy of a high-affinity anticarcinoembryonic antigen monoclonal antibody (COL-1). , 1993, Biotechnology therapeutics.
[33] S. Mirzadeh,et al. The Chemical Fate of 212Bi-DOTA Formed by β- Decay of 212Pb(DOTA)2-*** , 1993 .
[34] M. Kuroki,et al. TAG-72 as a Tumor Marker , 1992 .
[35] S. Mirzadeh,et al. Comparative biodistribution studies of DTPA-derivative bifunctional chelates for radiometal labeled monoclonal antibodies. , 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
[36] O. Gansow. Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelates. , 1991, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.
[37] M. Brechbiel,et al. An effective chelating agent for labelling of monoclonal antibody with 212Bi for α-particle mediated radioimmunotherapy , 1991 .
[38] J. Wesolowski,et al. Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities. , 1990, Human antibodies and hybridomas.
[39] S. Mirzadeh,et al. Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid ligands to immunoglobulin. , 1990, Bioconjugate chemistry.
[40] A. M. Friedman,et al. An improved generator for the production of 212Pb and 212Bi from 224Ra. , 1988, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.